Literature DB >> 15709006

Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes.

Naeem Khan1, Rachel Bruton, Graham S Taylor, Mark Cobbold, Thomas R Jones, Alan B Rickinson, Paul A H Moss.   

Abstract

Cytomegalovirus (CMV) elicits a potent T-cell response in humans that appears to protect the host from virus-associated disease. Despite facing strong host defense mechanisms, CMV remains as a lifelong infection that may reactivate and cause life-threatening disease in immunocompromised individuals. This persistence is probably assisted by expression of immune subversion proteins of the virus encoded by genes belonging to the US gene family. These proteins modulate major histocompatibility complex expression in infected cells and bias in vitro experiments toward the detection of only certain specificities. We have combined the use of recombinant CMV, lacking the US2 to US11 region genes, and cytoplasmic gamma interferon staining to define a more accurate assessment of CMV-specific responses in vivo. Recombinant CMV stimulation reveals a CD8 response much larger than that of parental virus in all donors tested. In some cases, this represented up to 10-fold increases in the number of cells detected. Responses were directed mainly against pp65, IE-1, and pp50 in the majority of donors. In addition, previously unreported IE-2-specific T-cell responses could be detected in a minority of cases. Furthermore, we observed a less marked increase in the response to mutant CMV by CD4 T cells in some donors. This suggests that a much broader T-cell response to CMV exists in vivo than is revealed by restimulation with wild-type virus and adds to the evidence that the efficacy of immune evasion strategies may not be as absolute as previously believed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709006      PMCID: PMC548448          DOI: 10.1128/JVI.79.5.2869-2879.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Infection of dendritic cells by murine cytomegalovirus induces functional paralysis.

Authors:  D M Andrews; C E Andoniou; F Granucci; P Ricciardi-Castagnoli; M A Degli-Esposti
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

4.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Authors:  G M Gillespie; M R Wills; V Appay; C O'Callaghan; M Murphy; N Smith; P Sissons; S Rowland-Jones; J I Bell; P A Moss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation.

Authors:  P J Lehner; J T Karttunen; G W Wilkinson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

6.  Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection.

Authors:  R J Rentenaar; L E Gamadia; N van DerHoek; F N van Diepen; R Boom; J F Weel; P M Wertheim-van Dillen; R A van Lier; I J ten Berge
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

7.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.

Authors:  D J Diamond; J York; J Y Sun; C L Wright; S J Forman
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

8.  Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens.

Authors:  Z Tabi; M Moutaftsi; L K Borysiewicz
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

9.  Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains.

Authors:  T R Jones; L Sun
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

10.  The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion.

Authors:  D G Kavanagh; M C Gold; M Wagner; U H Koszinowski; A B Hill
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  16 in total

1.  Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal.

Authors:  John A Zaia; Xiuli Li; Anne E Franck; Xiwei Wu; Lia Thao; Ghislaine Gallez-Hawkins
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

2.  Cytomegalovirus-Responsive CD8+ T Cells Expand After Solid Organ Transplantation in the Absence of CMV Disease.

Authors:  L E Higdon; J Trofe-Clark; S Liu; K B Margulies; M K Sahoo; E Blumberg; B A Pinsky; J S Maltzman
Journal:  Am J Transplant       Date:  2017-03-13       Impact factor: 8.086

3.  Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.

Authors:  Suzanne M McGoldrick; Marie E Bleakley; Abraham Guerrero; Cameron J Turtle; Tori N Yamamoto; Shalini E Pereira; Colleen S Delaney; Stanley R Riddell
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

4.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

5.  T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.

Authors:  Iulia Popescu; Matthew R Pipeling; Pali D Shah; Jonathan B Orens; John F McDyer
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

Review 6.  Diverse immune evasion strategies by human cytomegalovirus.

Authors:  Vanessa Noriega; Veronika Redmann; Thomas Gardner; Domenico Tortorella
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 7.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

Review 8.  Dynamics of T cell memory in human cytomegalovirus infection.

Authors:  Edward C P Waller; Elizabeth Day; J G Patrick Sissons; Mark R Wills
Journal:  Med Microbiol Immunol       Date:  2008-02-27       Impact factor: 3.402

Review 9.  Recombinant viruses as tools to study human cytomegalovirus immune modulation.

Authors:  Katrin Besold; Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2008-02-27       Impact factor: 3.402

10.  IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control.

Authors:  Iulia Popescu; Matthew R Pipeling; Hannah Mannem; Pali D Shah; Jonathan B Orens; Mark Connors; Stephen A Migueles; John F McDyer
Journal:  J Immunol       Date:  2015-12-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.